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Abstract 
Ovarian cancer is the 5th leading cause of cancer in women, affecting close to 22,000 women in the 
year 2011, of which nearly 15,500 will die. It is difficult to detect until it reaches advanced stages and 
becomes malignant. Currently, the standard treatment for ovarian cancer is platinum-based 
therapeutics, such as Carboplatin or Cisplatin, combined with Taxol. Unfortunately, approximately 
25% of patients are inherently platinum-resistant and all patients who suffer from recurrence will 
have developed acquired platinum resistance. The genetic/epigenetic causes of this resistance are 
poorly understood. Epigenetic events are reversible and the identification of genes altered by this 
mechanism may lead to studies on how to reprogram the process leading up to resistance. To 
examine the ovarian epigenome, we utilized an array based method, Methylation Oligonucleotide 
Microarray Analysis (MOMA), to analyze a set of 50 primary ovarian tumors and 12 ovarian normal 
samples. We identified epigenetic differences that segregated with platinum response and then 
associated this with expression data to identify gene candidates transcriptionally repressed and 
methylated in patients resistant to platinum. Next, a pooled shRNA screen was performed on 
candidate genes to identify those that were functionally relevant to platinum resistance. One of the 
validated candidate genes identified through the pooled shRNA screen was DOK2, an adapter 
protein downstream of tyrosine kinase, which has been shown by others to be a lung cancer tumor 
suppressor. We show that suppression of DOK2 by short hairpin RNAs in ovarian cell lines 
conferred resistance to platinum treatment. To elucidate the mechanism for resistance, we 
measured the influx of platinum into the cells using C-14 tagged carboplatin. As a result, uptake of 
carboplatin was found to be decreased with DOK2 suppression. Consistent with DOK2 having tumor 
suppressor activity, knockdowns in ovarian cell lines increases growth and migration. Furthermore, 
loss of DOK2 induces invasive and tumorigenic phenotypes in ovarian cell lines. DOK2 is already a 
proven tumor suppressor in lung cancer, and our experiments indicate DOK2 has tumor suppressor 
features in ovarian cancer as well. We show that DOK2 is a tumor suppressor in ovarian cancer and 
that the loss of DOK2 also contributes to platinum resistance. Understanding DOK2 function will help 
us understand ovarian cancer development, progression as well as therapy resistance. 
 
